Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score
Background: Treatment by immune checkpoint blockade (ICB) provides a remarkable survival benefit for multiple cancer types.However, disease aggravation occurs in a proportion of patients after the first couple of treatment cycles.Methods: RNA sequencing data was retrospectively collected.6 tumour-immune related features were extracted and combined